Research Papers:

CR6-interacting factor 1 inhibits invasiveness by suppressing TGF-β-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

Runzhou Zhuang, Di Lu, Jianyong Zhuo, Xuanyu Zhang, Kun Wang, Xuyong Wei, Qiang Wei, Wei Wang, Haiyang Xie, Lin Zhou, Xiao Xu _ and Shusen Zheng

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:94759-94768. https://doi.org/10.18632/oncotarget.21925

Metrics: PDF 1631 views  |   HTML 2123 views  |   ?  


Runzhou Zhuang1,3,*, Di Lu1,2,3,*, Jianyong Zhuo1,3, Xuanyu Zhang1,3, Kun Wang1,3, Xuyong Wei1,2,3, Qiang Wei1,2,3, Wei Wang1,3, Haiyang Xie1,3, Lin Zhou1,3, Xiao Xu1,2,3 and Shusen Zheng1,2,3

1Key Lab of Combined Multi-Organ Transplantation, Ministry of Public Health, Hangzhou 310003, China

2Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China

3Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China

*These authors have contributed equally to this work

Correspondence to:

Xiao Xu, email: [email protected]

Shusen Zheng, email: [email protected]

Keywords: CR6-interacting factor 1; hepatocellular carcinoma; TGF-β; EMT

Received: May 13, 2017    Accepted: August 09, 2017    Published: October 19, 2017


CR6-interacting factor 1 (CRIF1) regulates cell cycle progression and the DNA damage response. Here, we show that CRIF1 expression is decreased in hepatocellular carcinoma (HCC) tissues and positively correlates with patients’ survival. In vitro, down-regulation of CRIF1 promotes HCC cell proliferation and invasiveness, while over-expression has the opposite effect. in vivo, CRIF1 knockdown enhances growth of HCC xenografts. Analysis of mRNA microarrays showed that CRIF1 knockdown activates genes involved in TGF-β RI/Smad2/3 signaling, leading to epithelial-mesenchymal transition (EMT) and increased matrix metalloproteinase-3 (MMP3) expression. However, cell invasion and EMT are abrogated in HCC cells treated with SB525334, a specific TGF-β RI inhibitor, which indicates the inhibitory effect of CRIF1 on HCC tumor growth is mediated by TGF-β signaling. These results demonstrate that CRIF1 benefits patient survival by inhibiting HCC cell invasiveness through suppression of TGF-β-mediated EMT and MMP3 expression. This suggests CRIF1 may serve as a novel target for inhibiting HCC metastasis.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21925